RxDoctor Payments Data

Biqi Gao, MD

Family Medicine · Fremont, CANPI 1407869142

Payments from drug & device makers

$499in general payments, 2019–2025

Across 18 payments — averaging $27.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$158
  • Boehringer Ingelheim$70
  • Amgen$69
  • AbbVie$39
  • Merck$33
  • Sumitomo Pharma America, Inc.$27
  • plus $102 from 5 others

What the payments were for

  • Food & beverage$48497%
  • Education$153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$499 in reported general payments places this provider in the 60th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$62,023
Medicare patients
142
Services billed
482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$34,116
JanuviaSitagliptin Phosphate20$33,462
JardianceEmpagliflozin19$32,328
EliquisApixaban19$24,201
MounjaroTirzepatide15$16,125
MyrbetriqMirabegron13$10,054
Rosuvastatin Calcium47$3,127
Dexlansoprazole DrDexlansoprazole12$2,029
Atorvastatin Calcium168$1,837
Levothyroxine Sodium144$1,801
Estradiol11$1,565
PaxlovidNirmatrelvir/Ritonavir11$1,368
Metformin Hcl115$1,344
Losartan Potassium107$1,125
SynthroidLevothyroxine Sodium21$1,096

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$24$34,11626 claims
MerckJanuvia$33$33,46220 claims
Boehringer IngelheimJardiance$70$32,32819 claims
AbbVieSynthroid$39$1,09621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,533 family medicine providers in California.

Other family medicine in Fremont

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →